BioInformant

Your Global Leader in Stem Cell Market Research

Home » market news » Page 2

Why Perinatal Stem Cells Are Gaining Momentum

By Leave a Comment

Perinatal-Stem-Cell-SocietyRecently back from the Perinatal Stem Cell Society Conference in Aspen, CO, I am excited to share new coverage of the stem cell market with you. At this event, experts from around the world shared cutting-edge research about perinatal tissues over the course of three days (March 2-4, 2016).

We also have interviews with stem cell executives released below, including an interview with Dr. Jon Rowley, Founder and CEO of RoosterBio, and Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics. Enjoy this exclusive new content!

[Read more…]

Did You See This Week’s Top Stem Cell News?

By Leave a Comment

We’ve released new content on stem cell and cord blood markets that we are excited to share with you. Enjoy!

Q&A Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a broad range of diseases. Pluristem Therapeutics specializes in placental-derived “PLX” cells, which are now being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more. [Read more…]

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

By Leave a Comment

Pluristem Therapeutics marks its first entry into the defense sector with today’s breaking news. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).

To learn  more, read the full press issued by Pluristem, included below with permission from Janet Vasquez, Managing Director/Founder of JVPRVY. [Read more…]

We Interviewed Key Stem Cell Industry Leaders (Here’s What We Learned)

By Leave a Comment

In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced it is pursuing a Phase II clinical trial exploring spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of multiple sclerosis (MS).

Importantly, the Phase I trial was the first time in history that a treatment demonstrated reversal of established disability in MS patients. Therefore, we are excited to release an exclusive interview with Dr. Saud Sadiq, Chief Research Scientist for Tisch MSRCNY. [Read more…]

Creative Bioarray Launches New Primary Cell Products, including Human Hepatic Cells and Mouse Primary Cells

By Leave a Comment

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. The possibilities arising from stem cell characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, toxicology screening, and more.

To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged. One of the important segments within the stem cell research products market is primary cells products.

Today, Creative Bioarray of Shirley, New York, announced that it has expanded its product portfolio by adding new primary cells products that include human hepatic (liver) cells and mouse primary cells. To learn more, view the full press release below. [Read more…]

BioInformant's World-Class Clients